Pregnancy among participants in HIV prevention clinical trials continues to present a challenge. This study found that women who adopted an injectable contraceptive at the beginning of the trial were more likely to adhere to study product than women using combined oral contraceptives. HIV prevention trials should consider requiring long-acting methods, including injectables, for study participation.
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial
Written By
Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D, FEM-PrEP study group.
